Go et al. demonstrated that IVIG was an effective therapy in ITP patients without anti-GPIbα antibodies (7/7), whereas most patients with anti-GPIbα antibodies were refractory to this treatment (7/10) [137]. Here, GP1BA is linked to autoimmune thrombocytopenic purpura.